

CORNING

## **Advanced Models for 3D Screening: Immune Oncology Applications**


Hannah Gitschier, M.S.  
Applications Lab Manager  
Corning Life Sciences

AACR | April 2017

# Common methods for 3D multicellular tumor spheroid formation


## Parameters to consider

- Physiological relevance
- Cell-cell interactions
- Cell-ECM interactions
- Complexity
- Uniformity and reproducibility
- Scalability
- Compatibility with high-throughput screening
- Equipment investment
- Reagent volume
- Cost
- Long term culture




Breslin & O'Driscoll, 2013, *Drug Discov Today*. 18(5-6), 240-9


# Multicellular tumor spheroids: importance of the microenvironment




*HT-29 monolayer*



*HT-29 multicellular spheroids*




*HT-29 single spheroid per well*



Hirschhaeuser et al., 2010, *J. Biotechnol.*, 148(1), 3-15.

# Challenges with solid tumor immune cell therapy: Hostile tumor microenvironment

## Overcoming counter-attack and local immunosuppression




- Oxidative stress, nutrient depletion, low pH, hypoxia
- Suppressive soluble factors and cytokines
- Suppressive immune cells (Tregs, MDSC, M2-TAM / N2-TAN)
- “On target-off tumor”

Newick et al., 2016, *Mol. Ther. Oncolytics*, 3, 16006

# Advanced assay for detecting CAR-T mediated tumor spheroid cytotoxicity

## Flat-bottom microplate

2D Assay



Target cells seeded into 384-well microplate

24-48 hr.

CAR-T cells added


24 hr.

KILR Detection Reagent added

1 hr.

Detect luminescence

3D Assay




## Spheroid microplate


# CAR-T cell invasion of multicellular tumor spheroids

## HCC827 spheroids with CAR-T cell invasion


EGFR CAR-T E/T 0



EGFR CAR-T E/T 10




EGFR CAR-T E/T 40



*HCC827 spheroids formed using spheroid microplate for 48 hours. Twenty-four hours after ProMab Biotechnologies EGFR scFv-CD28-CD3ζ CAR-T cell addition, spheroids were stained for cytokeratin-7 (green) and CD3ε (red), with Hoescht nuclei counterstain (blue). As E/T ratio is increased from 10:1 to 40:1, invasion of the CAR-T cells into the HCC827 tumor spheroid and subsequent tumor cell lysis is visible. Images obtained using Thermo Fisher CellInsight CX7 in confocal mode using 10X objective.*


# Sensitivity of tumor cells to CAR-T cell mediated cytotoxicity shifted for 3D compared to 2D cell culture



- *Affinity-tuned scFvs exhibit higher anti-tumor efficacy to cells with higher expression of target receptor and no anti-tumor efficacy to cells exhibiting normal target receptor levels.*
- *HCC827 cells (lung adenocarcinoma) exhibit EGFR copy number amplification*
- *Second generation CAR-T cells targeting EGFR were used to target breast and lung cancer cell lines. Mock scFv Control CAR-T cells were used as negative control.*

# Challenges with solid tumor immune cell therapy: Migration and invasion



## Homing and infiltration




Ager et al., 2016, *Biochem. Soc. Trans.*, 44(2), 377-85




# Combining technologies to enhance 3D microenvironments



*A549 cells added to spheroid microplate for 3D multicellular spheroid formation*





*Transwell 96-well permeable support is inserted into spheroid microplate; NK cells added to insert.*



*Plates incubated together to allow for migration, spheroid infiltration, and cytotoxicity.*

# Immune cell migration and tumor spheroid infiltration in a single high-throughput screening amenable assay



- NK cell migration towards A549 multicellular tumor spheroids in the presence and absence of SDF-1 $\alpha$  (SDF) and/or prostaglandin E2 (PGE) in the medium*
- NK cell induced cytotoxicity of A549 multicellular tumor spheroids after migration. Percent cytotoxicity was calculated via flow cytometry by enumerating GFP positive A549 cells.*

# Acknowledgments

---


- Corning:
  - Audrey Bergeron
  - Hilary Sherman
  
- DiscoverRx:
  - Abhishek Saharia
  - Daniel Bassoni
  - Gaurav Agrawal
  
- ProMab:
  - Van Dang

# Appendix

Supplementary figures and slides



# Clinical Trials of CAR-T Therapy




- 374 clinical trials all over the world
- CAR targets include cancer, diabetes, AIDS, vascular diseases, etc.


[www.clinicaltrials.gov](http://www.clinicaltrials.gov), 3.14.2017

# CAR-T Cell Therapy

- T-cell therapy activates a patient's T cells against cancer with a chimeric antigen receptor (CAR) that recognizes an antigen expressed on the cancer cells.
- CARs are single-chain antibodies coupled to a transmembrane region and an intracellular signaling domain (e.g., from CD28 or 4-1BB).
- CARs against many tumor-associated antigens have been constructed and tested pre-clinically, and some have entered clinical trials




<https://www.mskcc.org/blog/car-t-cell-therapy-growing-area-research>



Front. Immunol., 14 November 2016 | <https://doi.org/10.3389/fimmu.2016.00500>

# CAR-T Cell Therapy



- CAR T cells face extra challenges with solid tumors:
  - Have to be made specific for an antigen whose expression clearly identifies tumor from normal tissue.
    - “on-target, off-tumor” cytotoxicity
  - Must be able to home and penetrate the fibrous connective tissue that surrounds the tumor.
  - Once within the tumor they must expand, persist and mediate cytotoxicity in a hostile environment with immunosuppressive modulators.



<http://www.nature.com/nbt/journal/v32/n7/full/nbt0714-604.html>

# Affinity-tuned CAR-T Cells from ProMab Biotechnologies


- ProMab Biotechnologies supplies second and third generation CAR-T cells targeting a variety of cell-surface receptors
- This study used a second generation construct with affinity-tuned scFvs targeting epidermal growth factor receptor (EGFR) and an empty vector Mock Control



Front. Immunol., 14 November 2016  
| <https://doi.org/10.3389/fimmu.2016.00500>




# DiscoverX® KILR® Assay




- The KILR assay from DiscoverX is a highly specific, non-radioactive measure of target cell death in a co-culture.
- KILR target cells are transduced to stably express a KILR reporter protein tagged with a  $\beta$ -gal fragment. This KILR reporter protein is released into the media upon cell death and lysis. Addition of detection reagents containing the other  $\beta$ -gal fragment results in a chemiluminescent output.

# Affinity-tuned CAR-T Cells & EGFR Targets

- This study used a second generation construct with affinity-tuned scFvs targeting epidermal growth factor receptor (EGFR) and an empty vector Mock Control from ProMab Biotechnologies



- For this study, 2 cell lines from the ATCC® EGFR Genetic Alteration Cell panel were selected:
  - HCC827 contains high EGFR copy number amplification
  - NCI-H460 contains no EGFR copy number amplification




Data from ATCC® Brochure

# Corning® spheroid microplates enable improved spheroid assays for screening



- Corning Ultra-Low Attachment (ULA) surface and unique round well-bottom design enable the formation and growth of a single, uniform spheroid per well with reproducible size.

Standard ANSI/SBS footprint dimensions for 96-well and 384-well formats

Clear bottom for visualization and imaging



Black sidewalls to reduce cross-talk and background noise in fluorescent- and luminescent-based assays




# Conclusions

- The Corning Epic BT reader is capable of performing label-free kinetic CAR-T assays at physiologically relevant temperatures.
- In combination with KILR Cytotoxicity Assay, the Corning spheroid microplate provides a high throughput platform for culturing and screening tumor spheroids with CAR-T cell assays.

- Deliverables
  - Both assays were presented as posters at SLAS in January
  - Both assays will be published as Application notes
  - A webinar will be co-hosted with DiscoverX and ProMab Biotechnologies on March 30<sup>th</sup>


**Label-free CAR-T Cell Assays with the Corning® Epic® BT: A High Throughput Kinetic System**

Audrey B. Bergeron B.S. and Hannah J. Glitscher M.S.  
Corning Incorporated, Life Sciences, Kennebunk, ME 04043



**DiscoverX** **CAR-T Cell Screening in Tumor Spheroids using Corning® Spheroid Microplates**

Audrey B. Bergeron B.S. and Hannah J. Glitscher M.S.  
Corning Incorporated, Life Sciences, Kennebunk, ME 04043



**Abstract**

Chimeric antigen receptor (CAR) T cells, which are engineered to recognize target cell surface antigens, represent an innovative cancer immunotherapy. However, applying the CAR-T cell to target tumors has been challenging. In addition to the immunological complexity of the tumor microenvironment, the immunological response of the CAR-T cells is often limited by the immunosuppressive environment of the tumor. The use of spheroid microplates to culture CAR-T cells and target cells in a high-throughput format allows for the study of CAR-T cell activity and target cell viability in a physiologically relevant environment. This approach allows for the study of CAR-T cell activity and target cell viability in a physiologically relevant environment. This approach allows for the study of CAR-T cell activity and target cell viability in a physiologically relevant environment.

**Spheroid CAR-T Assay Procedure**

1. HCT116 cells were cultured in Corning® Spheroid Microplates using the Spheroid Assay Kit (Cat. No. 3520-010).
2. CAR-T cells were cultured in Corning® Spheroid Microplates using the Spheroid Assay Kit (Cat. No. 3520-010).
3. CAR-T cells were co-cultured with HCT116 cells in Corning® Spheroid Microplates using the Spheroid Assay Kit (Cat. No. 3520-010).
4. CAR-T cells were co-cultured with HCT116 cells in Corning® Spheroid Microplates using the Spheroid Assay Kit (Cat. No. 3520-010).
5. CAR-T cells were co-cultured with HCT116 cells in Corning® Spheroid Microplates using the Spheroid Assay Kit (Cat. No. 3520-010).
6. CAR-T cells were co-cultured with HCT116 cells in Corning® Spheroid Microplates using the Spheroid Assay Kit (Cat. No. 3520-010).

**CAR-T Cell Invasion of Tumor Spheroids**

**KILR Cytotoxicity Assay from DiscoverX**

**ProMab CAR-T Cells**

**Spheroid Microplate**


**Assay Overview**

**ATCC® EGF1R Genetic Alteration Cell Panel**

**Conclusions**

**References**

**T Assay Results**




Condition	Target Cell Viability (%)	CAR-T Cell Viability (%)
Control	~100	~100
Target	~50	~100
Target + CAR-T	~20	~100

## Methods: Demonstrate Immune Cell Tumoricidal Activity

---

- Day 1: Seed 2,000 A549/GFP cells (cancer cells) per well of 96 well spheroid plate in IMDM 10%FBS
- Day 2: Label effector cells with CellTracker Blue and add to A549 spheroids at various concentrations
  - NK92-M1: natural killer cell line derived from peripheral blood known to be cytotoxic to a wide range of malignant cells
  - MOLT-4: T-cell leukemia cell line with no known cytotoxic effect on other malignant cells
- Day 3: Aspirate medium and replace with 150  $\mu$ L TrypLE™ Select Enzyme (10X) (Gibco™ Cat. No. A1217701) for 1 hour at 37°C or until spheroids could be broken up into single cells with minimal pipetting. Single cells were then analyzed via flow cytometry utilizing the Miltenyi Biotec MacsQuant®.


# Results: Demonstrate Immune Cell Tumoricidal Activity



Dose dependent effector function was demonstrated with NK cells and not MOLT-4 cells when added at various concentrations to A549 spheroids.


Data represents the average of 2 independent studies. N=12 per concentration.

## Results: Image Immune Cell Infiltration (Confocal)




Representative photomicrographs of A549/GFP spheroids with (right) and without (left) NK infiltration (200x). A549/GFP cells shown in green and NK-92MI cells shown in blue. Images taken at a Z stack height of -125  $\mu\text{m}$  via Thermo Scientific™ CellInsight™ CX7. Scale bar is 100  $\mu\text{m}$ .


## Results: Image Immune Cell Infiltration (Histology)



A549 only



A549 infiltrated with NK cells for 4 hours




A549 infiltrated with NK cells for 18 hours

200x CD45 (red) and e-cadherin stained (brown) sections of A549/GFP spheroids that were infiltrated by NK-92MI cells. Spheroids were fixed in 4 % paraformaldehyde (Boston Bioproducts Cat. No. BM-155) for cryostat sectioning and H&E staining (carried out at the University of New England, Biddeford, Maine).




# Results: Demonstrate Immune Cell Chemotactic Response




Dose dependent migration of NK cells towards SDF over a period of 24 hours. Data represents the average of 2 independent studies. N=24.

# Results: 2D versus 3D Immune Oncology Model



NK Migration towards 2D and 3D A549/GFP cells with or without SDF in the medium and with and without prostaglandin E2 inhibition of NK cells. Horizontal lines indicate statistical significance from a 1 way ANOVA with a Bonferroni's multiple comparison post test. \*\*\* = $p < 0.0001$  and \*\* = $p < 0.001$ . Data represents the average of 2 independent studies. N=24.

# Results: 2D versus 3D Immune Oncology Model



NK induced cytotoxicity of A549/GFP cells grown in 2D and 3D with or without SDF in the medium and with and without prostaglandin E2 inhibition of NK cells. Horizontal lines indicate statistical significance from a 1 way ANOVA with a Bonferroni's multiple comparison post test. \*\*\* = $p < 0.0001$ , \*\* = $p < 0.001$ , and \* = $p < 0.05$ . Data represents the average of 2 independent studies. N=24.

# Summary

---

- Effector cell cytotoxicity and specificity can be assessed using a combination of the spheroid microplate and flow cytometry.
- Transwell permeable supports can be utilized to assess NK migratory response towards chemoattractants such as SDF.
- The combination of the spheroid microplate and HTS Transwell-96 Well Permeable Supports allows for a novel 3D model that combines immune cell migration, effector induced cytotoxicity, and immune cell evasion in one easy to use model.

CORNING